10-Q · August 12, 2026
The provided filing extract does not include the financial statements or MD&A, so revenue, margins, EPS, balance-sheet trends, cash flow, and segment performance cannot be assessed. Management reported effective…
Earnings analysis · 10-Q
ARTL earnings analysis
Filed August 20, 2026 · Our reading of the company's report
The latest report
This Form 10-Q/A is an amendment limited to adding a FINRA arbitration claim that was omitted from the Original Report; it does not provide updated revenue, margins, EPS, cash flow, balance-sheet data, segment results,…
Read full summary
This Form 10-Q/A is an amendment limited to adding a FINRA arbitration claim that was omitted from the Original Report; it does not provide updated revenue, margins, EPS, cash flow, balance-sheet data, segment results, or guidance. Craft seeks an $880,000 success fee and warrants valued at $880,000 related to a private placement with approximately $11 million of gross proceeds, while Artelo has filed counterclaims. Management does not expect a material financial-statement impact, but the arbitration remains an additional legal and liquidity risk.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
What stood out
-
Amendment limited to legal disclosure
The August 20, 2026 Amendment adds the previously omitted Craft Capital Management arbitration disclosure and states that no other changes were made to the Original Report for the quarter ended June 30, 2026.
-
Company files arbitration counterclaims
Artelo submitted counterclaims on July 7, 2026 for fraudulent inducement, breach of contract, regulatory-rule violations, and declaratory relief in the ongoing arbitration.
-
Management expects no material impact
Management states it does not believe the arbitration’s ultimate resolution will have a material impact on consolidated financial statements, although the claim relates to a private placement that generated approximately $11 million of gross proceeds.
What to watch
-
Ongoing arbitration creates financial exposure
Craft seeks an $880,000 success fee, common-stock warrants valued at $880,000, monthly late fees, attorneys’ fees, interest, and other relief in connection with the March 30, 2026 private placement.
-
Litigation costs and execution risk
The arbitration process remains ongoing after Craft filed its claim on April 7, 2026 and the Company submitted counterclaims on July 7, 2026; the Company also acknowledges potential defense and settlement costs and management-resource diversion.
-
Dispute tied to major financing transaction
The disputed transaction generated approximately $11 million of gross proceeds, while Craft alleges breach of a right-of-first-refusal provision in the March 16, 2026 engagement letter after its termination on March 27, 2026.
Management's outlook
This Amendment No. 1 does not provide financial results, quantitative outlook, or guidance. It states that, except for the amended legal-proceedings disclosure and certifications, it makes no other changes to the Original Report.
Earlier filings 4
10-Q · May 14, 2026
Artelo Biosciences reported a net loss of $2.96 million for Q1 2026, increasing from $2.37 million in the prior year. The company's operating expenses rose to $2.69 million driven primarily by increased administrative…
10-K · February 24, 2026
Artelo is a clinical-stage biotech focused on lipid-signaling therapeutics (ART27.13, ART26.12, ART12.11). The 10‑K highlights positive clinical readouts: interim Phase 2a CAReS data for ART27.13 showed a mean +6.38%…
10-Q · August 13, 2025
Artelo Biosciences reported no revenue and a larger GAAP loss in Q2 2025: net loss of $(3,221) and loss per share of $(5.61), driven by higher operating expenses and financing activity. The company raised capital via a…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.